COVID-19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)-T-cell therapy
© 2023 Wiley Periodicals LLC..
More than 3 years have passed since Coronavirus disease 2019 (COVID-19) was declared a global pandemic, yet COVID-19 still severely impacts immunocompromised individuals including those treated with hematopoietic cell transplantation (HCT) and chimeric antigen receptor-T-cell therapies who remain at high risk for severe COVID-19 and mortality. Despite vaccination efforts, these patients have inadequate responses due to immunosuppression, which underscores the need for additional preventive approaches. The optimal timing, schedule of vaccination, and immunological correlates for protective immunity remain unknown. Antiviral therapies used early during disease can reduce mortality and severity due to COVID-19. The combination or sequential use of antivirals could be beneficial to control replication and prevent the development of treatment-related mutations in protracted COVID-19. Despite conflicting data, COVID-19 convalescent plasma remains an option in immunocompromised patients with mild-to-moderate disease to prevent progression. Protracted COVID-19 has been increasingly recognized among these patients and has been implicated in intra-host emergence of SARS-CoV-2 variants. Finally, novel SARS-CoV2-specific T-cells and natural killer cell-boosting (or -containing) products may be active against multiple variants and are promising therapies in immunocompromised patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 Suppl 1 |
|---|---|
| Enthalten in: |
Transplant infectious disease : an official journal of the Transplantation Society - 25 Suppl 1(2023) vom: 01. Nov., Seite e14144 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kampouri, Eleftheria [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antivirals |
|---|
| Anmerkungen: |
Date Completed 11.12.2023 Date Revised 11.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/tid.14144 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362639078 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362639078 | ||
| 003 | DE-627 | ||
| 005 | 20231227131645.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/tid.14144 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1226.xml |
| 035 | |a (DE-627)NLM362639078 | ||
| 035 | |a (NLM)37767643 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kampouri, Eleftheria |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)-T-cell therapy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.12.2023 | ||
| 500 | |a Date Revised 11.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Wiley Periodicals LLC. | ||
| 520 | |a More than 3 years have passed since Coronavirus disease 2019 (COVID-19) was declared a global pandemic, yet COVID-19 still severely impacts immunocompromised individuals including those treated with hematopoietic cell transplantation (HCT) and chimeric antigen receptor-T-cell therapies who remain at high risk for severe COVID-19 and mortality. Despite vaccination efforts, these patients have inadequate responses due to immunosuppression, which underscores the need for additional preventive approaches. The optimal timing, schedule of vaccination, and immunological correlates for protective immunity remain unknown. Antiviral therapies used early during disease can reduce mortality and severity due to COVID-19. The combination or sequential use of antivirals could be beneficial to control replication and prevent the development of treatment-related mutations in protracted COVID-19. Despite conflicting data, COVID-19 convalescent plasma remains an option in immunocompromised patients with mild-to-moderate disease to prevent progression. Protracted COVID-19 has been increasingly recognized among these patients and has been implicated in intra-host emergence of SARS-CoV-2 variants. Finally, novel SARS-CoV2-specific T-cells and natural killer cell-boosting (or -containing) products may be active against multiple variants and are promising therapies in immunocompromised patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a CAR-T-cell therapy | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antivirals | |
| 650 | 4 | |a convalescent plasma | |
| 650 | 4 | |a hematopoietic cell transplantation | |
| 650 | 4 | |a vaccine | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 650 | 7 | |a Receptors, Chimeric Antigen |2 NLM | |
| 700 | 1 | |a Hill, Joshua A |e verfasserin |4 aut | |
| 700 | 1 | |a Dioverti, Veronica |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transplant infectious disease : an official journal of the Transplantation Society |d 1999 |g 25 Suppl 1(2023) vom: 01. Nov., Seite e14144 |w (DE-627)NLM113005482 |x 1399-3062 |7 nnns |
| 773 | 1 | 8 | |g volume:25 Suppl 1 |g year:2023 |g day:01 |g month:11 |g pages:e14144 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/tid.14144 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 Suppl 1 |j 2023 |b 01 |c 11 |h e14144 | ||